Corrigendum: Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
- Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
by Lu, D.-S., Chen, C., Zheng, Y.-X., Li, D.-D., Wang, G.-Q., Liu, J., et al. (2018). Front. Mol. Neurosci. 11:155. doi: 10.3389/fnmol.2018.00155
In the original article, there was a mistake in Figure 6 as published. One western blot band of β-actin corresponding to TNF-α protein level 21 days after daily L-DOPA combined with ICA treatment in Figure 6B was inserted incorrectly. The corrected Figure 6 appears below.
Figure 6. ICA inhibited the neuroinflammation in LID after 6-OHDA-induced DA neuronal damage. The protein levels of neuroinflammatory factors, such as COX-2, IL-1β and TNF-α, in the SN were detected 7 (A) and 21 (B) days after daily L-DOPA (25 mg/kg, i.p.) combined with ICA (20 mg/kg, p.o.) treatment by western blotting. Data were shown as mean ± SEM from six rats (n = 6). *p <0.05 compared with the control group; #p <0.05 compared with 6-OHDA-treated group; Ψp <0.05 compared with 6-OHDA+L-DOPA group.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: Parkinson's disease, L-DOPA, dyskinesia, Icariin, combination treatment
Citation: Lu D-S, Chen C, Zheng Y-X, Li D-D, Wang G-Q, Liu J, Shi J and Zhang F (2020) Corrigendum: Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity. Front. Mol. Neurosci. 13:605722. doi: 10.3389/fnmol.2020.605722
Received: 13 September 2020; Accepted: 30 September 2020;
Published: 29 October 2020.
Edited and reviewed by: Jean-Marc Taymans, Institut National de la Santé et de la Recherche Médicale (INSERM), France
Copyright © 2020 Lu, Chen, Zheng, Li, Wang, Liu, Shi and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Feng Zhang, email@example.com
†These authors have contributed equally to this work